News

The approval is based on Prazaxa RE-LY trial, which demonstrated reduction in risk of stroke and systemic embolism by 35% beyond the reduction achieved with well controlled warfarin

With this milestone, Boehringer Ingelheim and MorphoSys have reached eighth clinical milestone during the year 2010. MorphoSys’ clinical pipeline now comprises 10 partnered programs in Phase 1 and

Adva-27a is a small molecule inhibitor of Topoisomerase II, an enzyme found in abundance in multi-drug resistant breast cancer as well as in other types of aggressive cancer.

The tablets will be available in 10mg, 20mg and 40mg. The most frequent adverse events reported by patients participating in clinical trials of Viibryd included diarrhoea, nausea, vomiting,

The HMS electronic health record (EHR) is 2011/2012 compliant in accordance with the criteria adopted by the Secretary of Health and Human Services. The certification enables providers to

Novartis said Gilenya prevents the white blood cells from reaching the CNS, where they could potentially attack the protective covering around the nerve fibers, resulting in less inflammatory

The acquisition will enhance Novartis‘s tools and services that aim to improve health outcomes for patients by advancing the ability to define and monitor individualized treatment programs. Under

The new software drivers allow the Hamilton MICROLAB VENUS software to control the KiNEDx arm by calling functions or through preprogrammed moves, and the user can easily make

Filed in 2009, the patent will cover inecalcitol doses higher than one milligram (mg) per day until 2029. Currently-marketed vitamin D analogues for indications such as rickets, osteoporosis